

November 6, 2020
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Chimerix Completes Rolling Submission of New Drug Application to FDA for Brincidofovir as a Medical Countermeasure for Smallpox

TOKYO, Japan, November 6, 2020 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") announced on November 5, 2020 (EST) that Chimerix has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of brincidofovir (BCV) for the indication of smallpox. SymBio, pursuant to a license agreement with Chimerix entered into on September 30, 2019, obtained the exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox), and SymBio is preparing to initiate a global study of BCV targeting adenovirus (AdV) infections occurring after hematopoietic stem cell transplantation.

Chimerix is developing BCV as a potential medical countermeasure for smallpox under an ongoing collaboration and funding provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services. For more information, please see Chimerix's website: <https://ir.chimerix.com/press-releases>

Mr. Fuminori Yoshida, President and Chief Executive Officer of SymBio, stated: "Chimerix's completion of the submission of the New Drug Application (NDA) for oral brincidofovir under the US FDA's rolling submission program is a major step forward for SymBio as well. Physicians in Europe and the United States have high expectations for brincidofovir, and we look forward to Chimerix receiving early approval of the oral formulation for the treatment of smallpox in the United States."

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Its two clinical-stage development programs are dociparstat sodium (DSTAT) and brincidofovir (BCV).

BCV is an antiviral drug candidate in development as a medical countermeasure for smallpox. For further information, please visit the Chimerix website, www.chimerix.com.

About the Global License Agreement for Brincidofovir

SymBio entered into an exclusive global license agreement with Chimerix Inc. (Headquarters: Durham, NC, "Chimerix") for brincidofovir (BCV) on September 30, 2019. Under the terms of the agreement, Chimerix grants SymBio exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of smallpox.

For further information, please see the SymBio's press release dated October 1, 2019,

<https://www.symbiopharma.com/news/20191001.pdf>

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.